Q1 2025 EMEA Venture Report (J.P. Morgan)

Summary

• Healthtech saw a 15% surge in venture capital investment in 2024.p.1
• More than $4 billion was invested into the EU's AI and biotech sectors in the first two months of 2025.p.1
• From December 2024 to February 2025, there were 58 VC-backed deals exceeding $50 million.p.1

Key insights

1. Healthtech venture capital investment surged 15% in 2024.p.1
2. AI and biotech still lead early-stage investment, with more than $4 billion invested in the EU's AI and biotech sectors in the first two months of 2025.p.1
3. There were 58 VC-backed deals exceeding $50 million between December 2024 and February 2025, indicating robust growth-stage activity.p.1
4. Geopolitical tensions affecting trade relations pose risks to companies and to exit markets.p.1
5. Fragmented regulations, especially in AI and fintech, create barriers and can stifle innovation in the EU.p.1